MSH3 and colorectal carcinoma: Because our true comparison was for survival of CRC patients with presumed loss of hMSH3 (hMutSβ) function compared to CRC patients who retain hMutSα and hMutSβ and hMutLα function (full DNA MMR proficiency), we analyzed our survival data in the absence of the 30 patients (13%) with MSI-H CRCs (all with hMutLα dysfunction).